32 completed, 4 terminated, 2 unknown. 26 Phase 2, 12 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 22, Terminated 2, Unknown 2 |
| Phase 1 | 12 | Completed 10, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow gp100 antigen: new trials by email Literature Review of gp100 antigen trials Research Report on gp100 antigen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma MART-1 antigen, IL-2, gp100 antigen - Melanoma (Skin) | Phase 1 | Completed | Mayo Clinic | 20 | 2007-03-01 | 2019-02-19 |
| LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery LMB-2 immunotoxin, MART-1 antigen, gp100 antigen - Melanoma (Skin), Non-melanomatous Skin Cancer | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 26 | 2005-12-01 | 2012-06-14 |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma cyclophosphamide, fludarabine phosphate, therapeutic autologous lymphocytes - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 58 | 2005-11-01 | 2013-06-06 |
| Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 1 | Completed | National Cancer Institute (NCI) | 2004-08-01 | 2015-04-30 | |
| Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma gp100 antigen, incomplete Freund's adjuvant, keyhole limpet hemocyanin - Melanoma (Skin) | Phase 1 | Completed | Providence Cancer Center, Earle A. Chiles Research Institute | 20 | 2004-07-01 | 2013-04-04 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma tyrosinase peptide, gp100 antigen, MART-1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-06-01 | 2015-04-15 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | University of Southern California | 42 | 2004-05-01 | 2014-05-22 |
| Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma gp100 antigen, incomplete Freund's adjuvant, ipilimumab - Melanoma (Skin) | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 179 | 2004-03-01 | 2012-06-22 |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma autologous dendritic cell-tumor fusion vaccine, gp100 antigen, therapeutic autologous dendritic cells - Melanoma (Skin) | Phase 2 | Unknown | Dana-Farber Cancer Institute | 40 | 2004-03-01 | 2009-02-09 |
| Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma aldesleukin, gp100 antigen, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 2 | Completed | National Cancer Institute (NCI) | 2003-09-01 | 2013-06-19 | |
| Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 60 | 2002-02-01 | 2014-05-22 |
| Vaccine Therapy in Treating Patients With Melanoma of the Eye MART-1 antigen, NA17-A antigen, gp100 antigen - Intraocular Melanoma | Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 13 | 2002-02-01 | 2012-09-24 |
| Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma gp100 antigen, incomplete Freund's adjuvant, ipilimumab - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | National Cancer Institute (NCI) | 2002-01-01 | 2013-06-20 | |
| Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 1 | Completed | University of Southern California | 19 | 2001-10-01 | 2014-05-22 |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye gp100 antigen, interleukin-2, MART-1 antigen - Extraocular Extension Melanoma, Recurrent Intraocular Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 2001-02-01 | 2024-03-04 | |
| Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma MART-1 antigen, gp100 antigen - Melanoma (Skin) | Phase 1 / Phase 2 | Unknown | Genzyme, a Sanofi Company | 2000-11-01 | 2014-01-06 | |
| Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma tyrosinase peptide, MART-1:27-35 peptide vaccine, gp100 antigen - Recurrent Melanoma, Stage IV Melanoma | Not applicable | Completed | National Cancer Institute (NCI) | 30 | 2000-10-01 | 2013-01-25 |
| Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 2 | Completed | Eastern Cooperative Oncology Group | 2000-09-01 | 2011-11-08 | |
| Vaccine Therapy in Treating Patients With Melanoma aldesleukin, gp100 antigen, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 2 | Completed | National Cancer Institute (NCI) | 2000-09-01 | 2013-06-19 | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 1 | Terminated | University of Southern California | 15 | 2000-06-01 | 2014-05-22 |
Showing 20 of 38. Sign in to see all of them.
Melanoma (36) · Uveal Melanoma (9) · Neoplasms (3) · Skin Neoplasms (3) · Carcinoma, Renal Cell (1) · Eye Neoplasms (1) · Urologic Neoplasms (1)
National Cancer Institute (NCI) (17) · University of Southern California (7) · National Institutes of Health Clinical Center (CC) (2) · Baylor Health Care System (1) · Dana-Farber Cancer Institute (1) · Duke University (1) · Eastern Cooperative Oncology Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Genzyme, a Sanofi Company (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Providence Cancer Center, Earle A. Chiles Research Institute (1) · University of Illinois at Chicago (1) · University of Virginia (1) · University of Wisconsin, Madison (1)
United States (37) · Belgium (1) · Denmark (1)
Steven A. Rosenberg, MD, PhD (10) · Jeffrey S. Weber, MD, PhD (6) · Jeffrey Weber (2) · Amy E. Bock (1) · Brian J. Czerniecki, MD, PhD (1) · Craig L. Slingluff, MD (1) · David Avigan, MD (1) · David M. Gustin, MD (1) · Douglas Schwartzentruber (1) · Francesco M. Marincola (1) · Frank Haluska, MD, PhD (1) · Hilliard F. Seigler, MD (1) · James C. Yang, MD (1) · Jan U. Prause, MD (1) · John M. Kirkwood, MD (1)
PMID 25667295, PMID 12684398, PMID 12826605, PMID 14581425, PMID 16087944, PMID 16237114, PMID 16699374, PMID 19228745, PMID 21631324, PMID 22021080
P30CA015083 (1), U01CA061498 (1)